- South Korea
- /
- Biotech
- /
- KOSDAQ:A196170
KRX Growth Companies With Insider Ownership Up To 28%
Reviewed by Simply Wall St
The South Korea stock market has tracked higher in back-to-back sessions, gathering almost 40 points or 1.5 percent along the way. Despite this recent uptick, concerns about a global economic slowdown have tempered investor optimism. In such a fluctuating market environment, identifying growth companies with significant insider ownership can provide investors with added confidence. Here are three KRX-listed growth companies where insiders hold up to 28% ownership, potentially signaling strong internal belief in their long-term prospects.
Top 10 Growth Companies With High Insider Ownership In South Korea
Name | Insider Ownership | Earnings Growth |
People & Technology (KOSDAQ:A137400) | 16.5% | 35% |
ALTEOGEN (KOSDAQ:A196170) | 26.6% | 72.9% |
Fine M-TecLTD (KOSDAQ:A441270) | 17.1% | 36.4% |
Global Tax Free (KOSDAQ:A204620) | 18.1% | 72.4% |
Seojin SystemLtd (KOSDAQ:A178320) | 29.6% | 58.7% |
Vuno (KOSDAQ:A338220) | 19.5% | 105% |
INTEKPLUS (KOSDAQ:A064290) | 16.3% | 77.4% |
UTI (KOSDAQ:A179900) | 33.1% | 122.7% |
HANA Micron (KOSDAQ:A067310) | 20% | 97.4% |
Techwing (KOSDAQ:A089030) | 18.7% | 77.8% |
Here's a peek at a few of the choices from the screener.
Daejoo Electronic Materials (KOSDAQ:A078600)
Simply Wall St Growth Rating: ★★★★★★
Overview: Daejoo Electronic Materials Co., Ltd. develops and sells electronic materials across various regions including South Korea, China, Taiwan, the United States, Europe, and Southeast Asia with a market cap of ₩1.74 trillion.
Operations: The company generates revenue primarily from the development, production, and sale of electrical and electronic components, amounting to ₩193.79 billion.
Insider Ownership: 28.9%
Daejoo Electronic Materials, with high insider ownership, is experiencing substantial growth. The company became profitable this year and its earnings are forecast to grow significantly at 55.82% per year, outpacing the Korean market. Despite a highly volatile share price recently and interest payments not being well covered by earnings, Daejoo's revenue is expected to grow 39% annually. Recent private placements raised KRW 61 billion, indicating strong investor confidence and supporting future expansion plans.
- Delve into the full analysis future growth report here for a deeper understanding of Daejoo Electronic Materials.
- Upon reviewing our latest valuation report, Daejoo Electronic Materials' share price might be too optimistic.
People & Technology (KOSDAQ:A137400)
Simply Wall St Growth Rating: ★★★★★★
Overview: People & Technology Inc. (KOSDAQ:A137400) specializes in providing coating, calendaring, slitting, automation, and other machinery services with a market cap of ₩1.33 trillion.
Operations: People & Technology Inc. generates revenue primarily from its Machinery & Industrial Equipment segment, amounting to ₩645.76 billion.
Insider Ownership: 16.5%
People & Technology, with high insider ownership, is set for robust growth. Its earnings are forecast to grow 35% annually, outpacing the Korean market's 29.5%. Revenue is expected to increase by 36.5% per year, significantly faster than the market's 10.1%. Despite recent shareholder dilution and a volatile share price over the past three months, the stock trades at a substantial discount of 63.6% below its estimated fair value, suggesting potential upside for investors.
- Unlock comprehensive insights into our analysis of People & Technology stock in this growth report.
- In light of our recent valuation report, it seems possible that People & Technology is trading behind its estimated value.
ALTEOGEN (KOSDAQ:A196170)
Simply Wall St Growth Rating: ★★★★★★
Overview: ALTEOGEN Inc., a biotechnology company, specializes in developing long-acting biobetters, proprietary antibody-drug conjugates, and antibody biosimilars with a market cap of ₩16.73 billion.
Operations: Revenue Segments (in millions of ₩): null
Insider Ownership: 26.6%
ALTEOGEN, with high insider ownership, is poised for significant growth. Its earnings are forecast to grow 72.95% annually and revenue by 48.7%, both outpacing the Korean market. The stock trades at a substantial discount of 72.2% below its estimated fair value despite recent shareholder dilution and share price volatility. The MFDS approval of Tergase® marks a pivotal milestone, transitioning ALTEOGEN to a commercial-stage company with superior product offerings in biologics.
- Click here and access our complete growth analysis report to understand the dynamics of ALTEOGEN.
- According our valuation report, there's an indication that ALTEOGEN's share price might be on the expensive side.
Make It Happen
- Reveal the 81 hidden gems among our Fast Growing KRX Companies With High Insider Ownership screener with a single click here.
- Shareholder in one or more of these companies? Ensure you're never caught off-guard by adding your portfolio in Simply Wall St for timely alerts on significant stock developments.
- Simply Wall St is your key to unlocking global market trends, a free user-friendly app for forward-thinking investors.
Ready To Venture Into Other Investment Styles?
- Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
- Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.
- Find companies with promising cash flow potential yet trading below their fair value.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
About KOSDAQ:A196170
ALTEOGEN
A bio company, focuses on developing long-acting biobetters, proprietary antibody-drug conjugates, and antibody biosimilars.
Exceptional growth potential with flawless balance sheet.